Appointed
Donald Kalkofen
Chief Financial Officer
GNVR ·
Genvor Inc
appointed Donald Kalkofen as the Company’s Chief Financial Officer effective as of May 18, 2026.
Ready 8-Ks
18
Latest filing
June 22, 2026, 4:15 PM ET
Top materiality
0.90
Event mix
leadership ×7 · other_material ×6 · other ×3
Sentiment
0 pos · 5 neg · 13 neu
Executive change
recent →
Recent 8-K filings for GNVR
Highest-materiality recent filing
Allure Worldwide completes reverse acquisition of Genvor; Genvor becomes wholly-owned subsidiary
- On May 27, 2022, Allure acquired Genvor in a reverse merger; Genvor shareholders received 35,261,871 shares (95% of Allure's outstanding stock).
- Genvor develops plant-based defense technology against Aflatoxins; has CRADA with USDA-ARS for corn seed trait development.
-
Deleted Evergreen's registration rights in side letter dated June 17, 2026.
-
Donald Kalkofen appointed CFO effective May 18, 2026; 20+ years biotech/tech CFO experience including IPO at Alpha Cognition.
-
Genvor creates Series C Preferred Stock with $300K conversion value, issues share to Brio Advisory
Series C Preferred Stock designated on May 5, 2026; 4 shares created, no preferential voting/dividends but conversion rights.
-
Genvor enters $800K convertible note deal with warrants and advisory pact
Issued $800,000 convertible promissory note (10% interest, 9-month maturity) to Evergreen Capital Management.
-
Genvor posts updated September 2025 corporate presentation on investor website
Presentation added to genvor.com/investors on September 4, 2025.
-
Chad Pawlak, Sr. elected to Genvor's Board of Directors
Chad Pawlak, Sr. was elected to the Board of Directors on November 12, 2024.
-
Director Judith S. Miller resigns from Genvor board effective August 7, 2024
Judith S. Miller resigned from Genvor's Board of Directors on August 7, 2024.
-
Genvor terminates CFO and Chief Business Officer Judith S. Miller effective May 29, 2024
Interim CFO & CBO Judith S. Miller terminated on May 29, 2024; reason not disclosed.
-
Genvor dismisses Turner Stone & Co as auditor; new firm Novogradac engaged
Turner, Stone & Company, LLP dismissed as independent auditor on March 17, 2024.
-
Genvor appoints Chad Pawlak CEO, reshuffles executive team; Miller becomes CBO and Interim CFO
Chad Pawlak appointed CEO with base salary of $300,000/year and up to 30% annual bonus tied to milestones.
-
Genvor restates financials for four periods due to $246k liability error
Non-reliance on financials for Sept 30, 2022, Dec 31, 2022, Mar 31, 2023, June 30, 2023.
-
Genvor restates financials for four quarters over $246K liability recording error
Independent accountant notified Genvor on Jan 9, 2024 that financials for periods ending Sept 2022 through June 2023 should no longer be relied upon.
-
Genvor launches new 'Investors' section on its website
Launched new website section at www.genvor.com on November 1, 2023.
-
Genvor formalizes Interim CEO Judith Miller's compensation with cash and milestone warrants
Cash fee of $20,000/month retroactive to June 20, 2023, accrued if funds unavailable.
-
Genvor terminates CEO Bradley White, appoints Judith S. Miller as Interim CEO
Bradley White terminated as officer effective June 20, 2023.
-
Allure Worldwide changes name to Genvor Incorporated; shareholders approve charter amendment
Name changed to Genvor Incorporated effective June 24, 2022 via Certificate of Amendment filed with Nevada.
-
Allure Worldwide discloses receipt of valuation report for Genvor Inc. subsidiary
Subsidiary Genvor Inc. received a valuation report; no specific valuation figures provided.
-
Allure Worldwide completes reverse acquisition of Genvor; Genvor becomes wholly-owned subsidiary
On May 27, 2022, Allure acquired Genvor in a reverse merger; Genvor shareholders received 35,261,871 shares (95% of Allure's outstanding stock).
Executive changes
Appointed
Chad Pawlak, Sr.
Director
GNVR ·
Genvor Inc
On November 12, 2024, Chad Pawlak, Sr. was elected as a Board of Directors of Genvor Incorporated (the “Company”).
Departed
Judith S. Miller
Director
GNVR ·
Genvor Inc
On August 7, 2024, Judith S. Miller resigned as a member of the Board of Directors of Genvor Incorporated (the “Company”).
Departed
(interim)
Judith S. Miller
Interim Chief Financial Officer and Chief Business Officer
GNVR ·
Genvor Inc
On May 29, 2024, Judith S. Miller was terminated as Interim Chief Financial Officer and Chief Business Officer of the Company.
Role change
(interim)
Judith S. Miller
member of the Board, Chief Business Officer, and Interim Chief Financial Officer
GNVR ·
Genvor Inc
Judith S. Miller resigned as the Company’s Interim Chief Executive Officer and was appointed as a member of the Company’s Board of Directors (the “ Board ”), as the Chief Business Officer of the Company, and as the Interim Chief Financial Officer of the Company
Appointed
Dr. Jesse Jaynes
Chief Scientific Officer
GNVR ·
Genvor Inc
Dr. Jesse Jaynes was appointed as the Chief Scientific Officer of the Company
Role change
Dr. Clayton Yates
scientific advisor
GNVR ·
Genvor Inc
Dr. Clayton Yates resigned as Chief Scientific Officer of the Company and was appointed as a scientific advisor for the Company
Appointed
Chad Pawlak
Chief Executive Officer
GNVR ·
Genvor Inc
Chad Pawlak was appointed as Chief Executive Officer of Genvor Incorporated
Appointed
(interim)
Judith S. Miller
Interim Chief Executive Officer
GNVR ·
Genvor Inc
Judith S. Miller was appointed as Interim Chief Executive Officer of the Company
Departed
Bradley White
Other Named Officer
GNVR ·
Genvor Inc
On June 20, 2023, Bradley White was terminated as an officer of Genvor Incorporated
Materiality & sentiment trend
Max materiality 0.90 · Median 0.53 · Most common event leadership